Growth hormone receptor antagonist treatment reduces exercise performance in young males.

Goto K, Doessing S, Nielsen RH, Flyvbjerg A, Kjaer M

The Journal of clinical endocrinology and metabolism23 Jun 2009Cited by 2 (Europe PMC)

PMID19549743DOI10.1210/jc.2009-0407PepBankPUB-19549743

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In healthy men, resting GH was higher with pegvisomant than placebo (P < 0.01).
In plain wordsIn healthy men, resting growth hormone was higher with pegvisomant than placebo.
Peptide
Pegvisomant
Outcome
IncreaseResting GH
Study
n = 20
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 mg/d · 16 dAs given in this study (human).
Source sentences
Summary
Conversely, resting serum GH concentration was significantly higher in the treatment group compared with the placebo group (P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects were treated with the GHR antagonist pegvisomant or placebo for 16 d.
Summary · context
Twenty healthy males participated in the study.InterventionSubjects were treated with the GHR antagonist (n = 10; 10 mg/d) or placebo (n = 10).
Report a problemFND-1954974302
02HumanNon-randomized trialEfficacy outcome
In healthy men, maximal oxygen uptake did not change significantly from baseline in either the pegvisomant or placebo group.
In plain wordsIn healthy men, maximal oxygen uptake did not change significantly from baseline with either pegvisomant or placebo.
Peptide
Pegvisomant
Outcome
No significant changeMaximal oxygen uptake
Study
n = 20
Comparator
Baseline
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
10 mg/d · 16 dAs given in this study (human).
Source sentences
Summary
VO(2 max) did not change significantly in either group after the treatment period.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects were treated with the GHR antagonist pegvisomant or placebo for 16 d.
Summary · context
Twenty healthy males participated in the study.InterventionSubjects were treated with the GHR antagonist (n = 10; 10 mg/d) or placebo (n = 10).
Report a problemFND-1954974303
03HumanNon-randomized trialEfficacy outcome
In healthy men, time to exhaustion at 90% of maximal oxygen uptake was shorter with pegvisomant than placebo (P < 0.05).
In plain wordsIn healthy men, pegvisomant shortened time to exhaustion during exercise compared with placebo.
Peptide
Pegvisomant
Outcome
DecreaseTime to exhaustion
Study
n = 20
Comparator
Placebo
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
10 mg/d · 16 dAs given in this study (human).
Source sentences
Summary
Time to exhaustion at 90% of VO(2 max) was significantly shorter in the treatment group (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects were treated with the GHR antagonist pegvisomant or placebo for 16 d.
Summary · context
Twenty healthy males participated in the study.InterventionSubjects were treated with the GHR antagonist (n = 10; 10 mg/d) or placebo (n = 10).
Report a problemFND-1954974304
04HumanNon-randomized trialEfficacy outcome
In healthy men, exercise-related serum free fatty acid changes did not differ significantly between pegvisomant and placebo.
In plain wordsIn healthy men, exercise-related free fatty acid changes did not differ significantly between pegvisomant and placebo.
Peptide
Pegvisomant
Outcome
No significant changeExercise free fatty acid changes
Study
n = 20
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 mg/d · 16 dAs given in this study (human).
Source sentences
Summary
No significant differences were observed between the groups in terms of changes in serum free fatty acids, glycerol, VO(2), or relative fat oxidation.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects were treated with the GHR antagonist pegvisomant or placebo for 16 d.
Summary · context
Twenty healthy males participated in the study.InterventionSubjects were treated with the GHR antagonist (n = 10; 10 mg/d) or placebo (n = 10).
Report a problemFND-1954974305
05HumanNon-randomized trialEfficacy outcome
In healthy men, exercise-related serum glycerol changes did not differ significantly between pegvisomant and placebo.
In plain wordsIn healthy men, exercise-related glycerol changes did not differ significantly between pegvisomant and placebo.
Peptide
Pegvisomant
Outcome
No significant changeExercise glycerol changes
Study
n = 20
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 mg/d · 16 dAs given in this study (human).
Source sentences
Summary
No significant differences were observed between the groups in terms of changes in serum free fatty acids, glycerol, VO(2), or relative fat oxidation.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects were treated with the GHR antagonist pegvisomant or placebo for 16 d.
Summary · context
Twenty healthy males participated in the study.InterventionSubjects were treated with the GHR antagonist (n = 10; 10 mg/d) or placebo (n = 10).
Report a problemFND-1954974306
06HumanNon-randomized trialEfficacy outcome
In healthy men, exercise oxygen uptake changes did not differ significantly between pegvisomant and placebo.
In plain wordsIn healthy men, exercise oxygen uptake changes did not differ significantly between pegvisomant and placebo.
Peptide
Pegvisomant
Outcome
No significant changeExercise oxygen uptake changes
Study
n = 20
Comparator
Placebo
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
10 mg/d · 16 dAs given in this study (human).
Source sentences
Summary
No significant differences were observed between the groups in terms of changes in serum free fatty acids, glycerol, VO(2), or relative fat oxidation.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects were treated with the GHR antagonist pegvisomant or placebo for 16 d.
Summary · context
Twenty healthy males participated in the study.InterventionSubjects were treated with the GHR antagonist (n = 10; 10 mg/d) or placebo (n = 10).
Report a problemFND-1954974307
07HumanNon-randomized trialEfficacy outcome
In healthy men, relative fat oxidation changes did not differ significantly between pegvisomant and placebo.
In plain wordsIn healthy men, fat oxidation changes did not differ significantly between pegvisomant and placebo.
Peptide
Pegvisomant
Outcome
No significant changeRelative fat oxidation changes
Study
n = 20
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 mg/d · 16 dAs given in this study (human).
Source sentences
Summary
No significant differences were observed between the groups in terms of changes in serum free fatty acids, glycerol, VO(2), or relative fat oxidation.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects were treated with the GHR antagonist pegvisomant or placebo for 16 d.
Summary · context
Twenty healthy males participated in the study.InterventionSubjects were treated with the GHR antagonist (n = 10; 10 mg/d) or placebo (n = 10).
Report a problemFND-1954974308
08HumanNon-randomized trialEfficacy outcome
In healthy men, pegvisomant decreased resting IGF-I by 20% from baseline (P < 0.05).
In plain wordsIn healthy men, pegvisomant lowered resting IGF-I by 20% from baseline.
Peptide
Pegvisomant
Outcome
DecreaseResting IGF-I
Study
n = 10
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 mg/d · 16 dAs given in this study (human).
Measurements
IGF-I reduction
20%
reported result
Source sentences
Summary
Resting serum IGF-I concentration decreased by 20% in the GHR antagonist-treated group (P < 0.05), whereas no change was observed in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects were treated with the GHR antagonist pegvisomant or placebo for 16 d.
Summary · context
Twenty healthy males participated in the study.InterventionSubjects were treated with the GHR antagonist (n = 10; 10 mg/d) or placebo (n = 10).
Report a problemFND-1954974301

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.